6
Registered trials
3
Recruiting
5
Unique sponsors
10
Unique IMPs
4
Commercial trials
Drug classes (ATC)
—
ATC code not specified
5
L
Oncology (ATC L)
2
Mechanism of action (INN-stem analysis)
Unknown / small molecule
3 substances
Kinase inhibitor
2 substances
Platinum compound
2 substances
Checkpoint inhibitor (PD-1)
1 substance
Antimetabolite
1 substance
Antibody-drug conjugate (ADC)
1 substance
Phase III:
1
Phase II:
3
Phase I (Other):
3
Phase III
1 trial-
RecruitingBayer AG Commercial3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; CARBOPLATIN; CISPLATIN; PEMBROLIZUMAB; PEMETREXED; SEVABERTINIB
Phase II
3 trials-
RecruitingBayer Consumer Care AG Commercial3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; SEVABERTINIB
-
RecruitingHet Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting AcademicPATRITUMAB DERUXTECAN; ZIRCONIUM (89ZR) PATRITUMAB DERUXTECAN
-
EndedVestre Viken HF AcademicOSIMERTINIB
Phase I (Other)
3 trials-
EndedBayer AG CommercialIMP not specified
-
PendingTOLREMO therapeutics AG CommercialIMP not specified
-
EndedBayer AG AcademicIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Bayer AG | Commercial | 3 | Phase I (Other), Phase III | 1 |
| TOLREMO therapeutics AG | Commercial | 1 | Phase I (Other) | 0 |
| Bayer Consumer Care AG | Commercial | 1 | Phase II | 1 |
| Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | Academic | 1 | Phase II | 1 |
| Vestre Viken HF | Academic | 1 | Phase II | 0 |
New trials by year
2024
3
2025
2